"Lenacapavir Approved: A Breakthrough in HIV Prevention for South Africa"

In March 2025, Gilead Sciences submitted lenacapavir to the South African Health Products Regulatory Authority, paving the way for a revolutionary HIV prevention method in South Africa by March 2026.

• The South African Health Products Regulatory Authority is set to review lenacapavir, a long-acting injection, which aims to significantly reduce HIV transmission rates in South Africa.
• During a recent roundtable, South Africas Minister of Health, Aaron Motsoaledi, announced plans to launch lenacapavir as a key strategy in the fight against AIDS by March 2026.
• Gilead Sciences, a leading biopharmaceutical company, developed lenacapavir, which offers a new approach to HIV prevention, enhancing treatment options available within the Department of Health and Social Care.